Previous 10 |
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas Strong balance sheet with cash, cash equivalents and marketable securities of $824.7million as of March 31, 2021 ...
The latest SPAC from Panacea Acquisition (NUVB), who took preclinical stage oncology company Nuvation Bio public through a reverse merger, will begin trading Wednesday, April 7, after staging $150M IPO in biotechnology sector.Panacea Acquisition Corp II prices its initial ...
Nuvation Bio (NUVB): FY Net loss of $41.7M.Cash and cash equivalents of $29.76MPress Release For further details see: Nuvation Bio reports FY results
Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update Closed business combination with Panacea, yielding new public listing and strong cash position of approximately $830 million Patient enrollment ongoing in Phase 1/2 study of NUV-422 in high-gr...
Nuvation (NUVB) announces that the U.S. FDA has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase ((CDK)) 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.Gliomas, which begin in the glial or supportive tissue, represent 75% of malignant primary b...
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas PR Newswire NEW YORK , March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...